Difficulty: Medium
Average Score: 63%
Practice
A 45-year-old man with a family history of hyperlipidemia and heart disease presents to the emergency department diaphoretic with chest pain radiating to his left arm. An ECG shows ST segment elevation in leads II, III, and aVF. The doctor administers alteplase intravenously. Which of the following markers would you expect to be elevated in this patient's blood as a direct result of alteplase?
Correct answer
C
Rationale
In this scenario, the correct answer is C) D-dimer. Alteplase is a thrombolytic medication used to dissolve blood clots in conditions like acute myocardial infarction (heart attack). When alteplase is administered to a patient with ST-segment elevation myocardial infarction (STEMI), it works by activating plasminogen to convert it into plasmin, which then degrades fibrin clots in the coronary arteries. This process leads to the release of degradation products, including D-dimer, into the bloodstream.
Option A) AST (Aspartate Aminotransferase) and option B) CK-MB (Creatine Kinase-MB) are markers used to assess cardiac damage, specifically in conditions like myocardial infarction. However, in this case, the primary mechanism of action of alteplase is thrombolysis, not direct myocardial injury, so these markers would not be directly influenced by alteplase administration.
Option D) Myoglobin is a marker for muscle injury and can be elevated in conditions like myocardial infarction as well. However, in the context of alteplase administration, the more specific marker to monitor for thrombolytic activity would be D-dimer.
Educationally, understanding the mechanisms of action and specific markers associated with different medications is crucial for healthcare professionals, especially in emergency situations like myocardial infarction. Being able to differentiate between markers of cardiac damage and markers of thrombolytic activity can guide clinical decision-making and patient management effectively.
Option A) AST (Aspartate Aminotransferase) and option B) CK-MB (Creatine Kinase-MB) are markers used to assess cardiac damage, specifically in conditions like myocardial infarction. However, in this case, the primary mechanism of action of alteplase is thrombolysis, not direct myocardial injury, so these markers would not be directly influenced by alteplase administration.
Option D) Myoglobin is a marker for muscle injury and can be elevated in conditions like myocardial infarction as well. However, in the context of alteplase administration, the more specific marker to monitor for thrombolytic activity would be D-dimer.
Educationally, understanding the mechanisms of action and specific markers associated with different medications is crucial for healthcare professionals, especially in emergency situations like myocardial infarction. Being able to differentiate between markers of cardiac damage and markers of thrombolytic activity can guide clinical decision-making and patient management effectively.